Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure

Circulation

Volumn 94, Issue 11, 1996, Pages 2800-2806

  Colucci, Wilson S ^a,l   Packer, Milton ^b   Bristow, Michael R ^c   Gilbert, E Michael ^d   Cohn, Jay N ^e   Fowler, Michael B ^f   Krueger, Steven K ^g   Hershberger, Ray ^h   Uretsky, Barry F ⁱ   Bowers, John A ^j   Sackner Bernstein, Jonathan D ^b   Young, Sarah T ^k   Holcslaw, Terry L ^k   Lukas, Mary Ann ^k  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Nebraska Heart Institute   (United States)

^h UNIVERSITY OF OREGON   (United States)

ⁱ PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^j Heart Institute of Nevada   (United States)

^k GLAXOSMITHKLINE   (United Kingdom)

^l BOSTON MEDICAL CENTER   (United States)

more..

Author keywords

antioxidants; carvedilol; heart failure; receptors, adrenergic, beta

Indexed keywords

CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; DYSPNEA; FATIGUE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 10544231452     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.11.2800     Document Type: Article

References (30)

1. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril in patients with mild to moderate heart failure. JAMA. 1988;259:539-544.
2. Francis GS, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. The neurohormonal axis in congestive heart failure. Ann Intern Med. 1984;101:370-377.
3. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
4. Colucci WS, Braunwald E. Pathophysiology of heart failure. In: Braunwald E, ed. Heart Disease. 5th ed. Philadelphia, Pa: WB Saunders Co; 1997:394-420.
5. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
6. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation. 1990;82:1724-1729.
7. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Renlund DG, Bristow MR. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:2426-2441.
8. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.
9. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol. 1994;23:943-950.
10. Eichhorn EJ, Heesch CM, Barnett JH, Alverez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-1320.
11. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773.
12. Dougherty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol. 1994;23:814-821.
13. Ruffulo RR, Gelai M, Heible JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38(suppl 2):S82-S88.
14. Yue T-L, Cheng H-Y, Lysko PC, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G, Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.
15. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678-1687.
16. Krum H, Sackner-Bernstein JD, Goldsmith R, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin H, Newberg GW, DeLong G, Packer M, Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in severe chronic heart failure. Circulation. 1995;92:1499-1506.
17. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225-1231.
18. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 1995;92:212-218.
19. Guyatt GH, Sullivan MJ, Thompson PS, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The six-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132:919-923.
20. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807-2816.
21. Packer M, Colucci WS, Sackner-Bernstein JD, Liang C, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH, and the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial. Circulation. 1996;94:000-000.
22. Cohn JN, Fowler MB, Bristow MB, Colucci WS, Gilbert EM, Kinal V, et al. Effects of carvedilol in severe chronic heart failure. J Am Coll Cardiol. 1996;27(suppl A):169A. Abstract.
23. Rector TS, Kubo SH, Cohn JN. Patients self-assessment of their congestive heart failure, pt 2: content, reliability and validity of a new measure, the Minnesota Living With Heart Failure Questionnaire. Heart Failure. 1987;3:198-209.
24. Sparrow J, Parameshar J, Poole-Wilson PA. Assessment of functional capacity in chronic heart failure: time-limited exercise on a self-powered treadmill. Br Heart J. 1994;71:391-394.
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
26. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group. Effect of carvedilol on morbidity and mortality in chronic heart failure. N Engl J Med. 1996;334:1349-1355.
27. Sackner-Bernstein J, Krum H, Goldsmith RL, Kukin ML, Medina N, Yushak M, Packer M. Should worsening heart failure early after initiation of beta-blocker therapy for heart failure preclude long-term treatment? Circulation. 1995;92(suppl I):I-395. Abstract.
28. Waagstein F, Caidahl K, Wallentin I, Bergh C, Hjalmarson A. Long term β-blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989;80:551-563.
29. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
30. Hart DJ, Katz SD, Lee SH, Ahern D, DeLong G, Whelan J, Packer M, Goldsmith RG. Characterization of the 9-minute self-powered treadmill walk, a new submaximal exercise test in patients with heart failure. J Am Coll Cardiol 1994;23:384A. Abstract.